دورية أكاديمية
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
العنوان: | Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT |
---|---|
المؤلفون: | Ramanan, Athimalaipet V., Dick, A.D., Jones, Ashley P., Hughes, Dyfrig, McKay, Andrew, Rosala_Hanna, Anna, Williamson, P.R., Hardwick, Ben, Hickey, Helen, Rainford, N, Kolamunnage-Dona, R, Culeddu, Giovanna, Plumpton, Catrin, Wood, Eifiona, Compeyrot-Lacassagne, Sandrine, Woo, P., Eldesten, C, Beresford, Michael W. |
المصدر: | Ramanan , A V , Dick , A D , Jones , A P , Hughes , D , McKay , A , Rosala_Hanna , A , Williamson , P R , Hardwick , B , Hickey , H , Rainford , N , Kolamunnage-Dona , R , Culeddu , G , Plumpton , C , Wood , E , Compeyrot-Lacassagne , S , Woo , P , Eldesten , C & Beresford , M W 2019 , ' Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT ' , Health Technology Assessment .... |
سنة النشر: | 2019 |
الوصف: | BACKGROUND: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab (Humira ®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be determined. OBJECTIVE: To compare the efficacy, safety and cost-effectiveness of adalimumab in combination with methotrexate (MTX) versus placebo with MTX alone, with regard to controlling disease activity in refractory uveitis associated with JIA. DESIGN: This was a randomised (applying a ratio of 2 : 1 in favour of adalimumab), double-blind, placebo-controlled, multicentre parallel-group trial with an integrated economic evaluation. A central web-based system used computer-generated tables to allocate treatments. A cost-utility analysis based on visual acuity was conducted and a 10-year extrapolation by Markov modelling was also carried out. SETTING: The setting was tertiary care centres throughout the UK. PARTICIPANTS: Patients aged 2-18 years inclusive, with persistently active JIA-associated uveitis (despite optimised MTX treatment for at least 12 weeks). INTERVENTIONS: All participants received a stable dose of MTX and either adalimumab (20 mg/0.8 ml for patients weighing < 30 kg or 40 mg/0.8 ml for patients weighing ≥ 30 kg by subcutaneous injection every 2 weeks based on body weight) or a placebo (0.8 ml as appropriate according to body weight by subcutaneous injection every 2 weeks) for up to 18 months. A follow-up appointment was arranged at 6 months. MAIN OUTCOME MEASURES: Primary outcome - time to treatment failure [multicomponent score as defined by set criteria based on the Standardisation of Uveitis Nomenclature (SUN) criteria]. Economic outcome - incremental cost per quality-adjusted life-year (QALY) gained from the perspective of the NHS in England and Personal Social Services providers. Full details of secondary outcomes are provided in the study protocol. RESULTS: A total of 90 participants were randomised (adalimumab, n = 60; placebo, n = 30). There were 14 (23%) treatment failures in the adalimumab group and 17 (57%) in the placebo group. The analysis of the data from the double-blind phase of the trial showed that the hazard risk (HR) of treatment failure was significantly reduced, by 75%, for participants in the adalimumab group (HR 0.25, 95% confidence interval 0.12 to 0.51; p < 0.0001 from log-rank test). The cost-effectiveness of adalimumab plus MTX was £129,025 per QALY gained. Adalimumab-treated participants had a much higher incidence of adverse and serious adverse events. CONCLUSIONS: Adalimumab in combination with MTX is safe and effective in the management of JIA-associated uveitis. However, the likelihood of cost-effectiveness is < 1% at the £30,000-per-QALY threshold. FUTURE WORK: A clinical trial is required to define the most effective time to stop therapy. Prognostic biomarkers of early and complete response should also be identified. TRIAL REGISTRATION: Current Controlled Trials ISRCTN10065623 and European Clinical Trials Database number 2010-021141-41. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 15. See the NIHR Journals Library website for further project information. This trial was also funded by Arthritis Research UK (grant reference number 19612). Two strengths of adalimumab (20 mg/0.8 ml and 40 mg/0.8 ml) and a matching placebo were manufactured by AbbVie Inc. (the Marketing Authorisation holder) and supplied in bulk to the contracted distributor (Sharp Clinical Services, Crickhowell, UK) for distribution to trial centres. |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | application/pdf |
اللغة: | English |
DOI: | 10.3310/hta23150 |
الإتاحة: | https://doi.org/10.3310/hta23150Test https://research.bangor.ac.uk/portal/en/researchoutputs/adalimumab-in-combination-with-methotrexate-for-refractory-uveitis-associated-with-juvenile-idiopathic-arthritis-a-rctTest(e71f87ca-6293-4d9a-a94a-cc45fd7e3b59).html https://research.bangor.ac.uk/ws/files/22989972/3028866.pdfTest |
حقوق: | info:eu-repo/semantics/openAccess |
رقم الانضمام: | edsbas.6D8908D9 |
قاعدة البيانات: | BASE |
ResultId |
1 |
---|---|
Header |
edsbas BASE edsbas.6D8908D9 904 3 Academic Journal academicJournal 903.687927246094 |
PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.6D8908D9&custid=s6537998&authtype=sso |
FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.3310/hta23150# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ramanan%2C+Athimalaipet+V%2E%22">Ramanan, Athimalaipet V.</searchLink><br /><searchLink fieldCode="AR" term="%22Dick%2C+A%2ED%2E%22">Dick, A.D.</searchLink><br /><searchLink fieldCode="AR" term="%22Jones%2C+Ashley+P%2E%22">Jones, Ashley P.</searchLink><br /><searchLink fieldCode="AR" term="%22Hughes%2C+Dyfrig%22">Hughes, Dyfrig</searchLink><br /><searchLink fieldCode="AR" term="%22McKay%2C+Andrew%22">McKay, Andrew</searchLink><br /><searchLink fieldCode="AR" term="%22Rosala%5FHanna%2C+Anna%22">Rosala_Hanna, Anna</searchLink><br /><searchLink fieldCode="AR" term="%22Williamson%2C+P%2ER%2E%22">Williamson, P.R.</searchLink><br /><searchLink fieldCode="AR" term="%22Hardwick%2C+Ben%22">Hardwick, Ben</searchLink><br /><searchLink fieldCode="AR" term="%22Hickey%2C+Helen%22">Hickey, Helen</searchLink><br /><searchLink fieldCode="AR" term="%22Rainford%2C+N%22">Rainford, N</searchLink><br /><searchLink fieldCode="AR" term="%22Kolamunnage-Dona%2C+R%22">Kolamunnage-Dona, R</searchLink><br /><searchLink fieldCode="AR" term="%22Culeddu%2C+Giovanna%22">Culeddu, Giovanna</searchLink><br /><searchLink fieldCode="AR" term="%22Plumpton%2C+Catrin%22">Plumpton, Catrin</searchLink><br /><searchLink fieldCode="AR" term="%22Wood%2C+Eifiona%22">Wood, Eifiona</searchLink><br /><searchLink fieldCode="AR" term="%22Compeyrot-Lacassagne%2C+Sandrine%22">Compeyrot-Lacassagne, Sandrine</searchLink><br /><searchLink fieldCode="AR" term="%22Woo%2C+P%2E%22">Woo, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Eldesten%2C+C%22">Eldesten, C</searchLink><br /><searchLink fieldCode="AR" term="%22Beresford%2C+Michael+W%2E%22">Beresford, Michael W.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Ramanan , A V , Dick , A D , Jones , A P , Hughes , D , McKay , A , Rosala_Hanna , A , Williamson , P R , Hardwick , B , Hickey , H , Rainford , N , Kolamunnage-Dona , R , Culeddu , G , Plumpton , C , Wood , E , Compeyrot-Lacassagne , S , Woo , P , Eldesten , C & Beresford , M W 2019 , ' Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT ' , Health Technology Assessment .... ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => BACKGROUND: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab (Humira ®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be determined. OBJECTIVE: To compare the efficacy, safety and cost-effectiveness of adalimumab in combination with methotrexate (MTX) versus placebo with MTX alone, with regard to controlling disease activity in refractory uveitis associated with JIA. DESIGN: This was a randomised (applying a ratio of 2 : 1 in favour of adalimumab), double-blind, placebo-controlled, multicentre parallel-group trial with an integrated economic evaluation. A central web-based system used computer-generated tables to allocate treatments. A cost-utility analysis based on visual acuity was conducted and a 10-year extrapolation by Markov modelling was also carried out. SETTING: The setting was tertiary care centres throughout the UK. PARTICIPANTS: Patients aged 2-18 years inclusive, with persistently active JIA-associated uveitis (despite optimised MTX treatment for at least 12 weeks). INTERVENTIONS: All participants received a stable dose of MTX and either adalimumab (20 mg/0.8 ml for patients weighing < 30 kg or 40 mg/0.8 ml for patients weighing ≥ 30 kg by subcutaneous injection every 2 weeks based on body weight) or a placebo (0.8 ml as appropriate according to body weight by subcutaneous injection every 2 weeks) for up to 18 months. A follow-up appointment was arranged at 6 months. MAIN OUTCOME MEASURES: Primary outcome - time to treatment failure [multicomponent score as defined by set criteria based on the Standardisation of Uveitis Nomenclature (SUN) criteria]. Economic outcome - incremental cost per quality-adjusted life-year (QALY) gained from the perspective of the NHS in England and Personal Social Services providers. Full details of secondary outcomes are provided in the study protocol. RESULTS: A total of 90 participants were randomised (adalimumab, n = 60; placebo, n = 30). There were 14 (23%) treatment failures in the adalimumab group and 17 (57%) in the placebo group. The analysis of the data from the double-blind phase of the trial showed that the hazard risk (HR) of treatment failure was significantly reduced, by 75%, for participants in the adalimumab group (HR 0.25, 95% confidence interval 0.12 to 0.51; p < 0.0001 from log-rank test). The cost-effectiveness of adalimumab plus MTX was £129,025 per QALY gained. Adalimumab-treated participants had a much higher incidence of adverse and serious adverse events. CONCLUSIONS: Adalimumab in combination with MTX is safe and effective in the management of JIA-associated uveitis. However, the likelihood of cost-effectiveness is < 1% at the £30,000-per-QALY threshold. FUTURE WORK: A clinical trial is required to define the most effective time to stop therapy. Prognostic biomarkers of early and complete response should also be identified. TRIAL REGISTRATION: Current Controlled Trials ISRCTN10065623 and European Clinical Trials Database number 2010-021141-41. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 15. See the NIHR Journals Library website for further project information. This trial was also funded by Arthritis Research UK (grant reference number 19612). Two strengths of adalimumab (20 mg/0.8 ml and 40 mg/0.8 ml) and a matching placebo were manufactured by AbbVie Inc. (the Marketing Authorisation holder) and supplied in bulk to the contracted distributor (Sharp Clinical Services, Crickhowell, UK) for distribution to trial centres. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3310/hta23150 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.3310/hta23150<br />https://research.bangor.ac.uk/portal/en/researchoutputs/adalimumab-in-combination-with-methotrexate-for-refractory-uveitis-associated-with-juvenile-idiopathic-arthritis-a-rct(e71f87ca-6293-4d9a-a94a-cc45fd7e3b59).html<br />https://research.bangor.ac.uk/ws/files/22989972/3028866.pdf ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.6D8908D9 ) |
RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3310/hta23150
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ramanan, Athimalaipet V.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dick, A.D.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jones, Ashley P.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hughes, Dyfrig
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => McKay, Andrew
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rosala_Hanna, Anna
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Williamson, P.R.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hardwick, Ben
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hickey, Helen
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rainford, N
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kolamunnage-Dona, R
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Culeddu, Giovanna
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Plumpton, Catrin
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wood, Eifiona
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Compeyrot-Lacassagne, Sandrine
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Woo, P.
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eldesten, C
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Beresford, Michael W.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => $2
[Type] => main
)
)
)
)
)
)
)
|
IllustrationInfo |